BioNTech/Pfizer COVID Vaccine Gets EU Panel Recommendation
Ticker: BNTX · Form: 6-K · Filed: Sep 20, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Sep 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, vaccine, covid-19, partnership
TL;DR
EU panel backs BioNTech/Pfizer's updated COVID shot for ages 12+.
AI Summary
On September 20, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of their Omicron-adapted bivalent vaccine for active immunization to prevent COVID-19 in individuals 12 years of age and older. This recommendation is based on clinical trial data demonstrating the vaccine's efficacy.
Why It Matters
This CHMP recommendation is a significant step towards broader availability of an updated COVID-19 vaccine in Europe, potentially impacting public health strategies and vaccine uptake.
Risk Assessment
Risk Level: low — The filing is an informational update regarding a regulatory recommendation, not a financial event that directly impacts BioNTech's immediate financial standing.
Key Players & Entities
- BioNTech SE (company) — Registrant
- Pfizer Inc. (company) — Collaborator
- Committee for Medicinal Products for Human Use (CHMP) (company) — Regulatory body
- September 20, 2024 (date) — Announcement date
- 12 years of age and older (age_group) — Vaccine indication
FAQ
What is the specific recommendation made by the CHMP?
The CHMP recommended the approval of BioNTech SE and Pfizer Inc.'s Omicron-adapted bivalent vaccine for active immunization to prevent COVID-19.
What is the age group for which the vaccine is recommended?
The vaccine is recommended for individuals 12 years of age and older.
Who announced this recommendation?
BioNTech SE and Pfizer Inc. announced the recommendation from the CHMP.
On what date was this announcement made?
The announcement was made on September 20, 2024.
What is the purpose of the vaccine?
The vaccine is for active immunization to prevent COVID-19.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-09-20 09:17:40
Filing Documents
- form6-kchmpopinion20sep2024.htm (6-K) — 17KB
- a99120240920_chmpopinionpr.htm (EX-99.1) — 64KB
- image_0.jpg (GRAPHIC) — 32KB
- image_1.jpg (GRAPHIC) — 69KB
- 0001776985-24-000081.txt ( ) — 221KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On September 20, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use ( " CHMP " ) of the European Medicines Agency ( " EMA " ) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date September 20, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union